User:Mr. Ibrahem/Secukinumab
-0522.jpg) Autoinjector of secukinumab by Novartis | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IL17A |
| Clinical data | |
| Trade names | Cosentyx |
| Other names | AIN457 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a615011 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| Drug class | Monoclonal antibody |
| Legal status | |
| Legal status | |
| Chemical and physical data | |
| Formula | C6584H10134N1754O2042S44 |
| Molar mass | 147944.37 g·mol−1 |
  (what is this?) (verify) | |
Secukinumab, sold under the brand name Cosentyx, is a medication used to treat psoriasis, ankylosing spondylitis, and psoriatic arthritis.[2] It is given by injection under the skin.[3]
Common side effects include a runny nose, diarrhea, cold sores, and hives.[3] Other side effects may include anaphylaxis and infection.[3] Use during pregnancy or breastfeeding is not recommended.[4] It is a monoclonal antibody that binds to and inhibits interleukin (IL)-17A.[3]
Secukinumab was approved for medical use in the United States and Europe in 2015.[3][2] In the United Kingdom 150 mg costs the NHS about £600 as of 2021.[4] This amount in the United States costs about 6,200 USD.[5]
References[edit]
- ^ "Cosentyx EPAR". European Medicines Agency (EMA). Archived from the original on 22 August 2020. Retrieved 23 September 2020.
- ^ a b c "Cosentyx". Archived from the original on 22 August 2020. Retrieved 11 October 2021.
- ^ a b c d e f "Secukinumab Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 11 October 2021.
- ^ a b BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1162. ISBN 978-0-85711-369-6.
{{cite book}}: CS1 maint: date format (link) - ^ "Cosentyx Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 22 June 2021. Retrieved 11 October 2021.